Komal K Javarappa
Overview
Explore the profile of Komal K Javarappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa A, Huuhtanen J, Vanttinen I, et al.
Blood
. 2022 Dec;
141(13):1610-1625.
PMID: 36508699
Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic leukemia (FAB M7) and are characterized by poor prognosis and limited...
2.
Okoye-Okafor U, Javarappa K, Tsallos D, Saad J, Yang D, Zhang C, et al.
J Exp Med
. 2022 Sep;
219(11).
PMID: 36053753
Thrombocytopenia, prevalent in the majority of patients with myeloid malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), is an independent adverse prognostic factor. Azacitidine (AZA), a mainstay...
3.
Ianevski A, Lahtela J, Javarappa K, Sergeev P, Ghimire B, Gautam P, et al.
Sci Adv
. 2021 Feb;
7(8).
PMID: 33608276
The extensive drug resistance requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to selectively target disease-driving cell subpopulations. To solve the combinatorial explosion challenge, we...
4.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, et al.
Leukemia
. 2020 Jul;
34(10):2780-2784.
PMID: 32678289
No abstract available.
5.
Kivioja J, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder M, et al.
Leukemia
. 2018 Dec;
33(6):1360-1372.
PMID: 30568173
Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated with unfavorable prognosis and represents a particularly challenging treatment group. To identify novel effective therapies for this AML subtype,...
6.
Javarappa K, Tsallos D, Heckman C
SLAS Discov
. 2018 Jun;
23(7):687-696.
PMID: 29865911
Myelosuppression is a major side effect of chemotherapy in cancer patients and can result in infections, bleeding complications, and increased risk of morbidity and mortality, as well as limit the...
7.
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa K, Majumder M, et al.
Blood
. 2017 Jun;
130(6):789-802.
PMID: 28619982
The bone marrow (BM) provides a protective microenvironment to support the survival of leukemic cells and influence their response to therapeutic agents. In acute myeloid leukemia (AML), the high rate...